Long Position on LABP @ $21.25 on 4/2/2024 (Fundamentals)

Landos Biopharma, Inc. (LABP), a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.

The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA.

The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease.

The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

AbbVie announced a definitive agreement to acquire Landos Biopharma to boost its portfolio in inflammatory and autoimmune disease drugs. Landos’ lead pipeline candidate is NX-13, which is in phase II development for the treatment of ulcerative colitis (UC). NX-13 is an oral NLRX1 agonist with a bimodal mechanism of action. It has the potential to treat UC and Crohn's disease with a new approach.

Entry Point: $21.25

Trading Range: $2.50 - $21.87

Stop Loss: $20.20

Target Price: $23.35

Position closed on 5/3/2024 at price of $22.25 with a 4.71% gain in 31 days.

Back to Portfolio